In conclusion, with the proof that Aβ therapeutics have a place in the fight against AD (51) and the observations in the current and other studies that selective inhibition of γ-secretase (18, 20) is possible and preclinical evidence that this is a more safer way forward (7, 17, 19, 21), further efforts to develop drugs that target specifically PSEN1–APH1B γ-secretase complexes seem an important goal for new therapeutic development. Here, APH1B is linked to Alzheimer disease.